HighGround

HighGround Bio is a biotechnology company focused on developing next-generation macrophage-based immunotherapies for the treatment of solid tumors and other complex diseases. Founded by pioneers in the field of CAR-macrophage technology, including Dr. Michael Klichinsky and Dr. Saul Priceman, the company leverages a proprietary platform to engineer myeloid cells with enhanced anti-tumor activity. HighGround Bio's approach aims to overcome the limitations of current T-cell therapies in solid cancers by utilizing the unique trafficking and phagocytic capabilities of macrophages to modulate the immunosuppressive tumor microenvironment. The company is currently in the pre-clinical stage, focusing on optimizing its lead candidates and expanding its pipeline of engineered cell therapies.